About US
Contact us
-
Daiichi Sankyo bags an industry first with Japanese nod for blood cancer drug EzharmiaWhile Daiichi Sankyo has been focusing on a stable of antibody-drug conjugates, the Japanese company has won a global first in an area that Pfizer is also targeting. Daiichi Sankyo has wo2022/10/12
-
Fierce Pharma Asia—Astellas-Seagen, Eisai-Merck, BeiGene-Novartis, Hengru share new cancer data at ESMOAt ESMO congress 2022, Seagen, Astellas and Merck showed how Padcev and Keytruda contributed to a combo in previously untreated bladder cancer. Three sets of liver cancer data by Merck and Eisai, Bei2022/10/10
-
Fierce Pharma Asia—Moderna's Japan plan; Takeda's cancer deal with Puma; Everest's new CEOModerna is considering building a manufacturing plant in Japan, its CEO says.Takeda has offloaded an unwanted cancer drug to Puma Biotechnology. Everest Medicines has hired former Gilead China head2022/10/10
-
Emergent wraps up purchase of Chimerix's potential monkeypox treatment TembexaWith the monkeypox virus evolving—just as the coronavirus before it—adding new products to combat its spread is a key priority for the U.S. Monday, Emergent BioSolutions took a step towar2022/9/29
-
COVID-19 tracker: BioNTech, Pfizer challenge two CureVac patents in EuropeCureVac's patent showdown with Pfizer and BioNTech has taken another turn. Plus, Merck inked a deal to expand the reach of its Ridgeback-partnered antiviral. Please read below for the lat2022/9/29
-
Eli Lilly hit with another age discrimination lawsuit—this time from a federal agencyAge discrimination lawsuits have been cropping up around the industry in recent years, and Eli Lilly is no stranger to such claims. Now, the company is defending against age discrimination allegation2022/9/27
-
Biogen finalizes $900M deal to settle whistleblower's long-running MS kickback suitYears into a whistleblower suit thatalleged illegal kickbacks to physicians, Biogen is now finally able to end thelegal saga just as the troubled drugmaker attends to a corporate restructuring. Bioge2022/9/27
-
Merck, defending its blockbuster Januvia, prevails in high-stakes patent lawsuit against ViatrisMerck & Co., after settling with nearly two dozen drugmakersaiming to launch generics of its blockbuster Type 2 diabetes med Januvia, has successfully parried a Viatris patent assault in court.2022/9/23
-
Novartis dons 'US-first' mindset amid groupwide overhaul, layoffs and generics spinoffDon’t mistake this for former U.S. President Donald Trump talking, but Novartis is taking a “U.S.-first” approach after lagging its Big Pharma peers in the world’s largest pharmaceuticals market.2022/9/23
-
BeiGene keeps its Brukinsa momentum going by winning NICE nod for rare lymphomaMore than a year after scoring an approval for Brukinsain Waldenstrom macroglobulinemia (WM) in the U.S., BeiGene appears poised to launch in that use in the U.K. Tuesday, England’s Natio2022/9/20